- Director, Pediatric Cystic Fibrosis Clinical Care Center, UH Rainbow Babies and Children's Hospital
- Director, LeRoy W Matthews, MD, Cystic Fibrosis Center, UH Rainbow Babies and Children's Hospital
- Co-Director, Pediatric Cystic Fibrosis Therapeutics Development Center, UH Rainbow Babies and Children's Hospital
- Director, Pediatric Aero-Digestive Program, UH Rainbow Babies and Children's Hospital
- Assistant Professor, CWRU School of Medicine
Erica Roesch, MD, is a specialist and clinical educator in pediatric pulmonary (lung) disease in the Division of Pediatric Pulmonology, Allergy, Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children’s Hospital since 2016. She sees patients at UH Rainbow Babies & Children’s main campus and UH Landerbrook Health Center.
Dr. Roesch trains fellows in Cystic Fibrosis outpatient care and is a lecturer in the fellowship's core and summer lecture series. She is a pulmonary clinical preceptor and inpatient service attending.
Dr. Roesch is board certified in pediatric pulmonology and pediatrics. Her academic interests include pediatric Cystic Fibrosis, bronchoscopy and aero-digestive. Her research focuses on Cystic Fibrosis and pulmonary translational research as well as quality improvement.
- Bronchopulmonary Dysplasia
- Chronic Lung Disease
- Cystic Fibrosis
- Pediatric Pulmonary Disorders
- Pediatric Pulmonology - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Pediatric Pulmonology
Pediatric Pulmonology - Uh Case Medical Center (2013 - 2016)
Residency | Pediatrics
Pediatrics - Kosair Children's Hospital - Norton Healthcare (2010 - 2013)
University Of Toledo College Of Medicine (2010)
Virginia Polytechnic Institute And State University (2005)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Erica Roesch did not disclose any Outside Relationships with Industry.